Products

Transforming Life Sciences through Strategic Investments

At Syncona, we are dedicated to transforming the life sciences landscape through strategic investments in innovative technologies. Our focus is on identifying and supporting late-stage clinical products that have the potential to make a significant impact on patient care and health outcomes.

Our Approach

Our strategy targets innovative life science companies with the potential for high returns and patient impact. We offer long-term support, guiding businesses from early development to successful market entry

POTOFOLIO IN NUMBERS

Unless stated all finance at 30 June 2024

£739m

Value of life sciences portfolio

13

High quality companies

19

Clinical trials across the portfolio

20-25

Portfolio of leading life science companies

3

New companies created or added per year

3-5

Companies to late-stage development

What we invest in

Therapeutics

Innovative treatments addressing unmet medical needs.

Biotechnology

Biological solutions that drive healthcare progress.

Medical Devices

Advanced tools improving patient care.

Diagnostics

Accurate diagnostics for better healthcare outcomes.